8-K: Tempest Therapeutics Reports Q1 2026 Results, Advances TPST-2003 Trial

Tempest Therapeutics announced first quarter 2026 financial results, highlighting positive interim data for its TPST-2003 CAR-T therapy in multiple myeloma and appointing a new Head of Business Development.

Summary

• Tempest Therapeutics reported its financial results for the quarter ended March 31, 2026.
• The company announced positive interim data from the REDEEM-1 Phase 1/2a trial of TPST-2003 in relapsed/refractory multiple myeloma (rrMM).
• All 15 CAR-T-nave efficacy evaluable patients treated with TPST-2003 across REDEEM-1 and POEMS-1 trials achieved a 100% complete response (CR) rate.
• The company selected Cincinnati Childrens Applied Gene and Cell Therapy Center (AGCTC) as its lead manufacturing partner for TPST-2003.
• Andrew Fang, Ph.D., was appointed as the Head of Business Development.
• Tempest Therapeutics ended the quarter with $1.8 million in cash and cash equivalents.
• The net loss for the quarter was $27.7 million, or $2.53 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to strong clinical data and strategic appointments, though the reduced cash position and increased net loss temper the overall sentiment.

Positives

• 100% complete response (CR) rate among all 15 CAR-T-nave efficacy evaluable patients treated with TPST-2003 across REDEEM-1 and POEMS-1 trials.
• Favorable safety profile with no Grade 3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) in the REDEEM-1 trial.
• Prior investigator-initiated trial (IIT) reached a median progression-free survival (PFS) of 23.1 months, including in patients with extramedullary disease.
• Appointment of Andrew Fang, Ph.D., as Head of Business Development to focus on strategic partnerships and corporate transactions.
• Closing of strategic asset acquisition of new dual-targeting CAR-T assets from Factor Bioscience Inc. and Erigen LLC.
• Delivery of the TPST-2003 lentiviral vector to AGCTC, supporting the planned initiation of a registrational study later this year.

Negatives

• Cash and cash equivalents decreased to $1.8 million from $7.7 million at the end of the previous quarter.
• Net loss for the quarter was $27.7 million, an increase from $10.9 million in the same period last year.
• General and administrative expenses increased by $2.1 million due to one-time costs from the asset acquisition.

Risks

• Tempest Therapeutics' need for additional capital to fund planned programs and operations and to continue as a going concern.
• Unexpected safety or efficacy data observed during preclinical or clinical trials.
• The possibility that results from prior clinical trials and preclinical studies may not be predictive of future results.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Loss of key personnel.
• Changes in expected or existing competition.
• Changes in the regulatory environment.
• Volatility and uncertainty in the capital markets for biotechnology companies.

Future Outlook

The company plans to initiate a U.S. registrational study for TPST-2003 in patients with rrMM later this year. A biologics license application (BLA) filing in China for TPST-2003 is planned for 2027. The company also anticipates shareholder approval for the 2026 Offering, which could provide up to $4 million in additional gross proceeds upon warrant exercise.

Management Comments

• "We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003."
• "We advanced key activities supporting the planned initiation of our U.S. registrational study of TPST-2003 in patients with rrMM, including announcing our lead manufacturing partner AGCTC and taking delivery of the TPST-2003 lentiviral vector, a critical component in the manufacturing of TPST-2003."
• "At the same time, we strengthened our ability to unlock value across our remaining portfolio with the appointment of Andrew Fang, Ph.D., as our Head of Business Development, whose focus on strategic partnerships, licensing and corporate transactions will help position us for long-term growth."
• "We believe these milestones further reinforce our momentum and our path toward delivering meaningful impact for patients and shareholders alike."

Industry Context

StockSavvy.ai notes that Tempest Therapeutics' focus on dual-targeting CAR-T therapies, particularly for relapsed/refractory multiple myeloma, aligns with the industry's push for more effective and differentiated oncology treatments. The positive interim data and strategic partnerships are crucial for advancing pipeline candidates in a competitive biotech landscape.

Comparison to Industry Standards

• The 100% CR rate in a small, efficacy-evaluable patient group for TPST-2003 is a strong signal, though direct comparison to industry standards requires larger, controlled trials. For context, CAR-T therapies for multiple myeloma like Abecma and Carvykti have shown high response rates in their respective pivotal trials, but often with different patient populations and safety profiles.
• The emerging favorable safety profile, specifically the absence of Grade 3 CRS or ICANS in the REDEEM-1 trial, is a key differentiator if sustained. Many CAR-T therapies face challenges with these severe adverse events, impacting patient eligibility and treatment protocols.
• The median PFS of 23.1 months from a prior IIT is competitive, but it's important to note this was an investigator-initiated trial and may not be directly comparable to company-sponsored registrational studies.

Management Changes

Stakeholder Impact

• Shareholders: Potential for future value creation through successful development of TPST-2003 and strategic partnerships, but also face risks associated with the company's cash runway and need for further capital.
• Employees: The appointment of a Head of Business Development may signal a strategic focus on growth and partnerships, potentially creating new opportunities.
• Patients: Positive clinical data for TPST-2003 offers hope for improved treatment options for relapsed/refractory multiple myeloma and POEMS syndrome.

Next Steps

• Initiate the first potentially registrational study to evaluate TPST-2003 in patients with rrMM later this year.
• Continue to expand outreach and partnering efforts in China.
• Plan for a biologics license application (BLA) filing in China for TPST-2003 in 2027.
• Seek shareholder approval for the 2026 Offering.

Key Dates

Recommendation

The strong clinical data for TPST-2003 is a significant positive, but the company's precarious cash position and the need for further capital raise and shareholder approval for the 2026 Offering warrant a cautious 'hold' rating. Investors should monitor the progress of the registrational study and future financing events.

Keywords

Tempest Therapeutics, TPST-2003, CAR-T, Multiple Myeloma, Clinical Trial, Biotechnology, Financial Results, REDEEM-1